Clinical Trial Update: PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. [Phase 3]

View source ↗

Summary

Phase III multicenter trial evaluating personalized apalutamide with post-operative radiation and androgen axis suppression for men with detectable PSA after pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Erleada (apalutamide) (apalutamide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Androgen Axis Suppression, Prostatectomy | Phase 3 | Status: RECRUITING